Fig. 1From: Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results6-months trastuzumab: Opinions on 4-year DFS. a Expected 4-year DFS of patients receiving 6-months trastuzumab. b Lowest acceptable 4-year DFS to change practice to 6-months trastuzumab. c Expected vs lowest acceptable levelsBack to article page